Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?

Abstract

Are new models needed to optimise the utilisation of new medicines to sustain healthcare systems?Godman B 1,2,3 , Malmström RE 4 , Diogene E 5 , Gray A 6 , Jayathissa S 7 , Timoney A 8 , Acurcio FA 9,10 , Alkan A 11 , Brzezinska A 12 , Bucsics A 13 , Campbell S 14,15 AbstractIntroduction: Medicines have made an appreciable contribution to improving health. However, even high income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimise their use. Objective: Review case histories among health authorities to improve the utilisation and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. Challenges and proposed models: A number of issues and challenges have been identified including the limited innovation level of new medicines alongside increasing requested prices for their reimbursement especially for oncology, orphan diseases, diabetes and HCV. Models centre on the three pillars of pre-, peri, and post-launch including critical drug evaluation and multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure Discussion: Proposed models which involve all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.

Quality of life of patients with Diabetes Mellitus Types 1 and 2 from a referal health centre in Minas Gerais, Brazil

“…Consequently, the population requiring either targeted prevention interventions or diabetes care, including the appropriate use of medicines, could soon exceed 1 billion [2,3,4]. This is relevant as diabetes is a principal cause of death worldwide [4,5], with considerable expenditure on the treatment of diabetes and its complications [1,3]. Diabetes also has a deleterious effect on patients' clinical, social, and economic status as well as their quality of life (QoL) and survival [6,7].…”

Análise de medicamentos novos registrados no Brasil na perspectiva do Sistema Único de Saúde e da carga de doença

“…The decision to introduce new drugs, in particular biological ones, in the health systems of countries with different levels of economic development is a challenge due to high costs, and requires economic analysis of the introduction of health technologies to guide the decision-making process 1 . The increasing trend of participation of new drugs in the therapeutic arsenal is evident in the studied cohort, whose share of biopharmaceuticals accounted for a quarter of drugs.…”

“…Medicines significantly contribute to the improvement of population health and patient survival 1 . Measures to improve public health are directed towards the prevention, inhibition, and modification of the natural course of diseases, as well as reduction of symptoms, these features are strongly influenced by access to and rational use of suitable drugs [1][2][3] .…”

“…Measures to improve public health are directed towards the prevention, inhibition, and modification of the natural course of diseases, as well as reduction of symptoms, these features are strongly influenced by access to and rational use of suitable drugs [1][2][3] . The ongoing demographic and epidemiological transitions in Brazil and in several other countries have resulted in a higher prevalence of chronic non-communicable diseases (CNCD), which cover health conditions wherein pharmacotherapy is an important therapeutic approach and prevention measure 1,4 . The pharmaceutical market is one of the most valuable and profitable in the world.…”

Influence of novel oral anticoagulants on anticoagulation care management

“…However, introduction of these pricey drugs in combination with many potential users could have a substantial impact on budgets. Therefore, health care authorities were looking for eff ective models to optimize their utilisation (11,12). NOACs were also introduced in Slovenia, like in many other countries, but there are diff erences between countries in the approach, activities, and reimbursement restrictions (11,13).…”